

**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Committee**

**Summary of Main Points from the Meeting held on Monday 13<sup>th</sup> July 2015**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the June 2015 meeting were approved and will be circulated.

**3. Matters Arising**

The Committee noted the matters arising from the previous meeting.

**4. Formulary Applications**

**Full applications**

- **Dapoxetine (Priligy®) 30mg and 60mg film coated tablets**

**Decision: Reject**

Dapoxetine is indicated for the treatment of premature ejaculation in adult men aged 18 to 64 years. It is the only licensed drug for this indication. Current formulary alternatives include paroxetine and fluoxetine, both of which are used off license for this indication. The panel thought that this type of drug should be managed within primary care, however the application for dapoxetine was rejected by NWLIF panel in September 2014.

- **NexoBrid 2g powder gel for gel**

**Decision: Accept**

NexoBrid® is indicated for the removal of eschar in adults with deep partial and full thickness thermal burns. There are currently no formulary alternatives and so provides an alternative solution to the current standard of care which consists of surgical excision of the burn. The panel and Dr Leon-Villapalos agreed that it would be included to the formulary under the following criteria, which would be reviewed in a year:

- Consultant prescribing only
- For full thickness burns only
- For burns <5% total body surface area

- **Nivolumab 10mg/ml solution for infusion (Opdivo®)**

**Decision: Accept**

Nivolumab is intended to be used for relapsed squamous cell NSCLC where licensed treatment options are exhausted/not appropriate. It will be supplied via an Expanded Access Programme for up to 24 months or until included on the Cancer Drugs Fund List or 90 days after the date when guidance recommending use of the drug is issued by NICE.

- **Meningococcal group B Vaccines (Bexsero®)**

**Decision: Accept**

Meningococcal Group B Vaccines is indicated for the use in:

- Children and adults with asplenia, splenic dysfunction or complement disorder (including those on complement inhibitor treatment)
- Neonates / infants: As part of the childhood immunisation policy from September 2015, newborn aged 2 months will be offered the MenB vaccine, which protects against meningococcal B disease, followed by a second dose at 4 months and a booster at 12 months. This public health initiative is funded by the DoH and the trust will not be charged for these patients

**Individual funding requests (For noting)**

- **IFR – Apremilast for sarcoidosis (For noting)**

**Decision: Noted**

For the management of a specific patient with sarcoidosis

- **IFR – Fampridine for downbeat nystagmus (For noting)**

**Decision: Noted**

For the management of a specific patient with downbeat nystagmus

- **IFR – Alitretinoin Sjogren Larsson Syndrome (For approval)**

**Decision: Rejected**

For the management of a specific patient with Sjogren Larsson Syndrome.

This IFR was discussed and the panel rejected it due to the patient's age and that switching treatment to alitretinoin should be considered when the patient was older.

**Ex-Panel Requests**

- Tocilizumab 162mg pre-filled syringe

**Decision: Approved**

**5. Trust Medicines Policy**

- **TMP Audit Action Plan 2014/15**

Trust Medicines Policy Audit 2014/15 - Action plan as of June 2014.

- **TMP Audit standards 2015/16**

## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Committee

Trust Medicines Policy Audit 2015/16 - Audit Standards.

- **Policy for the Safe Prescribing, Handling and Administration of Systemic Anti-Cancer Treatment Drugs**  
Annual updates to the policy for peer review.

- **Intrathecal Cytotoxic Chemotherapy Policy**  
Updates to the policy for peer review.

- **Policy for the safe dispensing, labelling and administration of vinca alkaloids**  
Updates to the policy to comply with Peer Review standards.

### 6. Medicines Management

- **Shortage of Ketamine 10mg/ml injection Memo**

**Decision: Noted**

Trustwide memo circulated to Paediatric wards/theatres/A&E and NICU, in light of a shortage of ketamine 10mg/ml injection.

- **Trust PGD Lead**

**Decision: Noted**

Vacancy for Trust PGD Lead.

- **PSA: Risk of death or severe harm due to inadvertent injection of skin preparation solution**

**Decision: Noted**

Relating report.

- **Trust IV Administration Guide**

**Decision: Noted**

Full updated Trust IV Administration Guide

### 7. NICE TA Guidance

6 Technology Appraisals for June 2015.

- TA339 – Omalizumab for previously treated chronic spontaneous urticaria

**Action: Add to formulary. Short application form received**

- TA340 – Ustekinumab for treating active psoriatic arthritis

**Action: Add to formulary pending a short application form from rheumatologists**

- TA341 – Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

**Action: Currently included in formulary. To update formulary to indicate that apixaban is to be used in line with NICE TA341. Short application form received.**

- TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis

**Action: Add to formulary. Full application form received.**

- TA343 – Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

**Action: Add to formulary. Short application form received**

- TA344 – Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

**Action: Add to formulary. Short application form received**

### **NHSE Specialised Commissioning Policies**

- SSC1527 – Specialised Commissioning Services Circular in relation to TA343 and TA344

**Decision: Noted**

- Clinical Commissioning Policy Statement: Treatment of chronic hepatitis C in patients with Cirrhosis

**Decision: Noted**

### 8. IVIG Update

**Decision: Noted**

- **IVIG requests**

There were 13 IVIG issues in June 2015, with 8 new requests:

- Two for inflammatory myopathies (blue indication)
- Four for ITP (red indication)
- One for haemolytic disease of the newborn (red indication)

**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Committee**

- One for Post exposure prophylaxis for tetanus (GREY indication)

**9. Items for noting**

- **MHRA Update**

June 2015

- **NWLIF Compliance audit Q1 2015/2016**

Audit of prescribing compliance with the NWLIF Q1 2015/2015

- **PGD Tracker**

PGD tracker as of July 2015

**10. Meeting minutes for noting**

- Nil

**13. Date of next meeting**

**Monday 7<sup>th</sup> September: 8.00 - 9.00**

**Board Room: Lower Ground Floor, Lift Bank B**

**Closing date for papers: Friday 21<sup>st</sup> August 2015**